Squamous cell carcinoma of the head and neck presents a treatment challenge owing to the complexity of the anatomy of the head and neck region. Till recently, tobacco and alcohol were thought to be the main risk factors. Recently, human papilloma virus (HPV) has gained significant attention in the etiology of oropharyngeal cancer. Depending on the location of the tumor, surgery as a primary treatment can be quite debilitating due to cosmetic as well as functional reasons. Nonsurgical (radiotherapy or chemoradiotherapy) modalities are preferred as initial treatments of oropharynx, hypopharynx and larynx primaries. A multidisciplinary approach is recommended for treatment of these malignancies.
INTRODUCTION

Squamous cell carcinoma of the head and neck (SCCHN)
is diagnosed in excess of half a million patients worldwide. It is the most common histologic subtype, accounting for 85 to 95% of cancers of the head and neck. The other anatomic sites-thyroid gland and salivary glands have cancers that are common histologic variants of adenocarcinoma and will not be included in this discussion. Chemotherapeutic agents that have activity against SCCHN include but are not restricted to platinum agents (cisplatin and carboplatin), fluorouracil (5-FU), docetaxel, paclitaxel, methotrexate, vinorelbine and bleomycin. Of these, the platinum agents, 5-FU and taxanes are most active and form the backbone of most chemotherapeutic regimens. Recently, biologic agents have also been shown to be active, the most widely used agent being Cetuximab which is a monoclonal antibody to the epidermal growth factor receptor (EGFR).
Chemotherapy use in SCCHN can be divided into the following categories which will be addressed in this review. Important studies are summarized in Table 1. • Postoperative chemoradiotherapy (adjuvant treatment) • Sequential chemoradiotherapy (induction chemotherapy followed by definitive local therapy) • Concomitant chemoradiotherapy for organ preservation • Concomitant chemoradiotherapy for unresectable disease • Chemotherapy for recurrent and/or metastatic disease.
Biologic therapy (cetuximab) can be used in the following settings:
• Concomitant with radiotherapy for unresectable disease or organ preservation • Recurrent/metastatic disease.
Issues in management of nasopharyngeal cancer are quite different which are addressed below. However, cisplatinbased concurrent chemoradiotherapy is essentially the standard for management of locally advanced nasopharyngeal cancer.
POSTOPERATIVE CHEMORADIOTHERAPY (ADJUVANT TREATMENT)
Two randomized trials clarified the role of postoperative chemoradiotherapy as adjuvant treatment. These studies conducted by European organization for research and treatment of cancer (EORTC) 1 and radiation therapy oncology group (RTOG) 2 addressed the question of whether the addition of cisplatin to standard postoperative radiotherapy based on pathologic criteria would improve the outcome of patients. The experimental arms of both studies consisted of standard fractionation radiation with concurrent cisplatin (100 mg/m 2 ) on days 1, 22, and 43.
The 5-year results of the EORTC study indicated significant improvement in progression-free survival (47% compared with 36%, p = 0.04), and overall survival (53% compared with 40%, p = 0.02) in favor of concurrent cisplatin plus radiation. The findings of the RTOG study initially demonstrated a significant advantage with combinedmodality adjuvant therapy for the first two outcomes, but not for overall survival (3-year survival was 56% compared with 47%; p = 0.09). In both studies, toxicity was greater with concurrent chemoradiotherapy. Although the treatment was very similar, the high-risk pathologic features were not uniform and the study populations differed. The entry criteria for the RTOG study were the presence of multiple positive nodes, extracapsular extension of tumor, or a positive margin. In contrast, the EORTC trial defined high risk as positive margin, extracapsular extension of nodal disease, vascular embolisms, or perineural disease; for oral cavity or oropharynx primary sites, high risk was defined as positive nodes at level IV or V. These differences may partly explain the variable outcome of the two trials. In an effort to reconcile these two trial results, a pooled analysis was performed that showed that the subsets of patients in both trials with significant benefit from cisplatin added to radiotherapy had either microscopically involved margins or extracapsular extension of disease in neck nodes. 3 The presence of either or both of these risk factors is, therefore, considered a definite indication for adjuvant chemoradiotherapy.
SEQUENTIAL CHEMORADIOTHERAPY (INDUCTION CHEMOTHERAPY FOLLOWED BY DEFINITIVE LOCAL THERAPY)
In the 1980-2000 period there were multiple trials evaluating the role of induction chemotherapy followed by definitive local treatment. [4] [5] [6] [7] [8] [9] [10] [11] Chemotherapy regimens were mainly cisplatin based combinations with cisplatin and 5-FU dominating the literature in the 1990s. In spite of high antitumor activity of the induction chemotherapy, all but two trials did not show a benefit of induction chemotherapy for locoregional control or overall survival. In one of the randomized controlled trial, 237 patients with stages III and IV cancer of the oral cavity, oropharynx, hypopharynx, or paranasal sinus were randomly assigned to receive standard treatment or four cycles of cisplatin and 5-FU infusion followed by standard treatment. 8 The trial included patients with resectable or unresectable disease. The control arm, or standard local-regional treatment, was prospectively determined for each patient based on their resectability status. There was no difference in overall survival or localregional control between the two groups, although there was a significant reduction in the incidence of distant metastases with the addition of chemotherapy. were all in favor of the three drug regimen. Incidence of distant metastasis was similar in both arms. Based on the above trials, when induction chemotherapy is considered, docetaxel, cisplatin and 5-FU should be the standard of care.
CONCOMITANT CHEMORADIOTHERAPY FOR ORGAN PRESERVATION
Organ preservation is particularly important for tumors of the oropharynx (preserve swallowing) and larynx/ hypopharynx (preserve voice). Initial studies conducted were based on induction chemotherapy for patients with resectable disease while subsequent studies focused on concurrent chemoradiotherapy. It was larynx preservation that set the tone for organ preservation. The department of veterans affairs laryngeal cancer study group (VALSCG) conducted a randomized study involving 332 patients with resectable T2-T4 laryngeal cancer. Patients were randomized to total laryngectomy followed by adjuvant radiation or to three cycles of induction cisplatin and 5-FU followed by radiation. Surgery was reserved for patients who had an inadequate response, persistent disease or relapse in the latter group. 15 The larynx was preserved in 64% of patients overall and in 64% of long-term survivors. There were more local recurrences and fewer distant recurrences in the chemotherapy group. Overall survival was similar between the two groups. On multivariate analysis, T4 and N2 disease significantly predicted treatment failure with 56% of T4 lesions requiring laryngectomy eventually. A similar study was conducted by the EORTC with resectable T2-T4 hypopharynx cancer. Randomized patients received either primary surgery followed by radiation or three cycles of induction therapy with cisplatin and 5-FU followed by radiation. Of note, only complete responders after 2 or 3 cycles on induction chemotherapy received radiation. Nonresponders and partial responders received surgery. Locoregional failures were similar in the 2 arms, while distant recurrences were fewer in the induction chemotherapy arm as compared to the primary surgery arm (25% vs 36%). Although median survivals were 44 months in the induction chemotherapy arm and 25 months in the immediate surgery arm, these were statistically not significant. More importantly, at five years, 35% of patients in the induction chemotherapy arm had an intact larynx. These two studies, established induction chemotherapy followed by radiation as an organ preservation strategy. Subsequently, interest in concurrent chemoradiotherapy arose, and in fact the Intercrop 91-11 study randomized 547 patients with T2-low-volume T4, nonmetastatic squamous cell cancers of the larynx to radiotherapy alone, radiotherapy with concomitant cisplatin administered on days 1, 22 and 43, or induction cisplatin and 5-FU, followed by radiotherapy for patients having a partial or complete response to induction chemotherapy at the primary site. 16 Neck dissection was performed for all patients initially presenting with N2 or N3 disease. Laryngectomy was performed for patients with insufficient response, persistent disease or local recurrence. Two year larynx preservation rates were 88% in the concomitant chemoradiotherapy arm compared with 75% in the induction arm (p = 0.005) and 70% in the radiotherapy alone arm (p < 0.001). Locoregional control was also superior in the concomitant arm (78% vs 61% vs 56% respectively). Distant metastasis free survivals were superior the chemotherapy arms as compared to radiation alone arm (61% vs 52% vs 44%). Overall survival was similar in all three groups.
For the oropharynx tumors, the Group d'Oncologie Radiotherapie Tete et Cou (GORTEC) randomized 226 patients with stage III or IV squamous cell cancer of the oropharynx to radiotherapy alone, or radiotherapy with concomitant carboplatin (70 mg/m 2 ) and 5-FU (600 mg/m 2 daily continuous infusion for 4 days) starting on days 1,22 and 43 of radiation. 17 Three-year disease free survival (42% vs 20%) and overall survival (51% vs 31%) were superior in the combined modality arm. Mucositis, requirement of feeding tube, treatment related weight loss and myelosuppression was greater in the combined arm.
CONCOMITANT CHEMORADIOTHERAPY FOR UNRESECTABLE DISEASE
Multiple studies were published from 1990-2000, addressing the role of chemotherapy in addition to radiotherapy for unresectable SCCHN. [18] [19] [20] [21] 
CHEMOTHERAPY FOR INCURABLE RECURRENT/METASTATIC DISEASE
Chemotherapy for incurable recurrent or metastatic disease is palliative and is usually platinum based. Cisplatin or carboplatin, with or without 5-FU is currently the standard regimen for this subgroup. The benefit obtained from addition of 5-FU is modest at best. In a phase III trial, 249 patients with recurrent head and neck cancers were randomized to cisplatin alone, 5FU alone or the combination. Although the combination arm had increased response rates, there was no increase in overall survival in the combination arm. 24 On subgroup analysis, OS benefit was limited to patients with good performance status or poorly differentiated histology. Combination chemotherapy should be reserved for good performance status patients who might be in a better position to benefit from the increased response rates. The addition of taxanes to the armamentarium of drugs was anticipated to improve the outcome in the subgroup. Unfortunately, this was not the case. In a phase III trial, patients with metastatic, recurrent or locally advanced head and neck cancers were randomized to cisplatin and 5-FU or cisplatin and taxol. There was no difference in response rates (27% vs 26%) or OS (8.7 months vs 8.1 months).
The benefit of adding the anti-EFGR monoclonal antibody cetuximab was recently shown to improved outcomes in this group of patients and is addressed below.
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WHERE DO WE STAND NOW? CONCURRENT CHEMORADIOTHERAPY OR INDUCTION THERAPY FOLLOWED BY DEFINITIVE LOCAL THERAPY?
The data incorporating docetaxel in the induction regimen is fairly recent. 13, 14 Concurrent cisplatin-based chemoradiotherapy has a long track record in terms of improving locoregional control and in fact is superior to CF based induction chemotherapy for the same. 16 However, TPF is superior to CF for locoregional control. 14 Induction chemotherapy has superior outcomes in terms of reducing distant metastasis while that of concurrent treatment is at best questionable. 8 Induction therapy runs the danger of causing toxicities to the patient thereby delaying definitive treatment. The debate between these two approaches exists since there is no comparative trial that has data mature enough to state the advantage of one over the other. Each case should be evaluated on an individual basis by a multidisciplinary team in terms of addressing the risks of local and distant disease. It is also important for the multidisciplinary team to be involved in the care of these patients right from the start so that induction therapy can be aborted and definitive treatment started at the earliest in case of toxicities. Off protocol, it is reasonable to use induction chemotherapy among patients who need therapy immediately. It is also reasonable to use it in patients with bulky primaries (T4 disease) and advanced nodal presentations (N2b, N2c, and N3 disease).
Preliminary data comparing these two approaches in patients with unresectable disease has been presented. 26 In this phase III randomized study, 439 patients with locally advanced unresectable SCCHN were randomized to three cycles of induction chemotherapy (PF or TPF) followed by standard dose radiotherapy with concurrent cisplatin at 100 mg/m 2 on days 1, 22 and 43 (arm 1) or chemoradiotherapy alone (arm 2). 26 Median time to treatment failure was 12.5 months in arm 1 vs 4.9 months in arm 2. Locoregional control rates were 61% and 44.5% respectively. Grade 3 and 4 toxicities were higher in arm A. Febrile neutropenia rates were 10% and 1% respectively. Of note, overall survival was 37 months and 27 months but not statistically significant (HR 0.85; 0.63-1.15). Final publication is awaited.
BIOLOGIC THERAPY
Epidermal growth factor receptor (EGFR) is expressed in virtually all SCCHN and its presence is associated with a worse prognosis. [27] [28] [29] EGFR is a member of the Erb-B family of receptors that are activated by numerous ligands. Activation leads to dimerization of the receptors which is followed by a series of changes that eventually leads to activation of transcription factors that regulate gene expression involved in cell migration, adhesion, proliferation, angiogenesis and inhibition of apoptosis (Fig. 1) . 30 Targeting EGFR seems a logical way of improving outcomes in SCCHN. Cetuximab is an IgG1 monoclonal antibody that inhibits ligand binding to EGFR and also promotes antibody dependant cell-mediated cytotoxicity. [31] [32] [33] In a landmark trial, 424 patients with locoregionally advanced SCCHN were randomized to cetuximab plus radiotherapy or radiotherapy alone. Cetuximab was given at 400 mg/m 2 as initial dose followed by 250 mg/m 2 every week. 34 Median duration of locoregional control was 24.4 months in the combined treatment arm as compared to 14.9 months in the radiotherapy alone arm. Overall survivals were 49 months and 29.3 months respectively. Grade 3 or higher toxic effects that were higher in the cetuximab arm were acneiform rash and infusion reactions. Other toxicities including mucositis were similar. Of note grade 3-4 radiation dermatitis rates were 23% in the combined arm and 18% in the radiation alone arm. Radiation dermatitis which is classically within the radiation fields should be distinguished from the characteristic acneiform rash (Fig. 2) . A recent survey of the EORTC institutes showed that the rate of severe radiation dermatitis was approximately 49% in patients treated concurrently with cetuximab and radiation. 35 The management of radiation dermatitis with or without cetuximab is addressed elsewhere. 36 Of note, there was no chemotherapy arm in this study so it is impossible to make a comparison between cisplatin-based radiation and cetuximab-based radiation. RTOG 0522 is a randomized phase 3 study comparing accelerated radiotherapy and cisplatin with or without cetuximab. It has closed to accrual and we will have to wait a few years before any efficacy data is available. Till then, cetuximab with radiotherapy should be considered for patients with locally advanced SCCHN who are unfit for cisplatin-based chemotherapy. It should not be used in addition to cisplatin and radiotherapy off study. Cetuximab has also shown activity in the advanced disease setting (Table 2 ). In a randomized phase III study, 442 patients with previously untreated recurrent or metastatic disease were randomized to cisplatin 100 mg/m 2 . 25 The addition of cetuximab led to an improvement in response rates from 20 to 36%, prolonged median PFS from 3.3 to 5.6 months and median OS from 7.4 to 10.1 months. Grade 3 and 4 toxicities that were greater in the cetuximab arm included sepsis (4% vs <1%), rash (9% vs <1%) and infusion reactions (3% vs 0%). ECOG 5397 was a study that randomized patients 117 patients to cisplatin in combination with cetuximab or cisplatin alone. 37 Although the response rates were increased in the combination arm (26% vs 10%), this did not translate into an improvement in overall survival (9.2 vs 8.0 months, p = 0.21). In another study, patients with disease progression on two to six cycles of platinum therapy received single-agent cetuximab (initial dose 400 mg/m 2 followed by subsequent weekly doses of 250 mg/m 2 ). Response rate was 13% and median time to progression was 70 days. 38 Cetuximab is currently approved in combination with radiotherapy for locally advanced SCCHN and in patients with recurrent or metastatic disease progressing after platinum based chemotherapy. Patients should be monitored for serum magnesium periodically during treatment since hypomagnesemia is a known complication of cetuximab. Erlotinib and gefitinib are oral tyrosine kinase inhibitors that act by inhibiting the phosphorylation of EGFR intracellularly. They have only modest clinical activity in SCCHN when used as single agents. 39, 40 A three arm study compared oral gefitinib at 250 mg/day or 500 mg/day vs methotrexate 40 mg/m 2 weekly intravenously. There was no difference in survival between the three arms (median survivals were 5.6 months, 6.0 months and 6.7 months respectively). Of note, there was an increase in tumorhemorrhage type events in the gefitinib groups (8.9%, gefitinib 250 mg/day, 11.7%, gefitinib 500 mg/day, and 1.7%, methotrexate). 41 Studies are underway of combining these agents with chemotherapy in the first line setting in advanced disease. 42 Approximately 90% of patients had stage 4 disease, and WHO subtype 1 was the commonest histology. The combined modality arm was superior to the radiation alone arm in terms of 5-year progression-free survival (58% vs 29%, p < 0.001), and overall survival (67% vs 37%). Of note, approximately two-third of patients received all three doses of concurrent cisplatin and half received all three cycles of adjuvant cisplatin and 5-FU). Two other studies conducted in endemic areas have shown a significant survival advantage with concurrent platinum chemotherapy and radiation over radiation alone. 43, 44 These results have also been confirmed in two meta-analysis. 45, 46 Induction chemotherapy followed by radiotherapy as compared to radiotherapy alone have not been shown to improve overall though there have been mixed results in terms of progression-free survival. [47] [48] [49] A recent randomized phase 2 study showed a survival advantage for induction chemotherapy with cisplatin and taxotere for 2 cycles followed by chemoradiotherapy with weekly cisplatin as compared to the same chemoradiotherapy arm alone. The 3-year progression free survival for the neoadjuvant vs control arm was 88% and 59% while overall survival was 94% and 68% respectively. Induction chemotherapy for NPC is not recommended out of a protocol setting. Taking into account the data above, radiation with concurrent cisplatin at 100 mg/m 2 on days 1, 22 and 43 followed by 3 cycles of cisplatin (80 mg/m 2 ) and 5-FU (1000 mg/m 2 /day for 4 days) should be the standard of care for patients with stage IIB-IV NPC.
NASOPHARYNGEAL CANCER (NPC)
NPC
FUTURE DIRECTIONS
Management of SCCHN has evolved over the last few decades. Several advances have been made in terms of chemotherapeutic drugs, radiotherapy techniques and management of toxicities. However, novel approaches are required to improve the outcomes that platinum-based regimens have achieved. Incorporation of cetuximab is an important step in that direction. The results of RTOG 0522 are eagerly awaited. Meanwhile, the field of oncology has seen an explosion in the field of targeted therapy. Several of these agents in addition are being studied in phase 1 and 2 trials. Some of these agents are bevacizumab, sunitinib and cedarinib of which bevacizumab and sunitinib are already approved for other malignancies. If results are encouraging, it would be exciting to bring these drugs into frontline management.
KEY POINTS
• Concurrent cisplatin and radiation is the standard of care for adjuvant treatment of tumors that have positive microscopic margin or extracapsular extension • If induction chemotherapy is planned, the preferred regimen is taxotere, cisplatin and 5-FU (TPF) • Debate between induction therapy with TPF followed by local treatment vs concurrent chemoradiation needs to be resolved. At this point, every case should be managed on an individualized basis • Organ preserving strategies should be sought for tumors of the larynx, hypopharynx and oropharynx. Surgery should be used only in the salvage setting • For unresectable SCCHN radiation with high dose cisplatin is the current standard of care • Monoclonal antibody therapy with cetuximab in combination with radiation is an appropriate option for patients who need concurrent treatment but cannot tolerate chemotherapy.
• Results of cetuximab in addition to chemotherapy and radiation are eagerly awaited. Till then, cetuximab should not be combined with cisplatin and radiation in a nonprotocol setting
• Additional studies using oral EGFR inhibitors and vascular endothelial growth factor inhibitors in advanced disease are eagerly awaited • Nasopharyngeal cancer frequently presents with stage III and IV disease. Cisplatin and radiation given concurrently followed by three cycles of cisplatin and 5-FU is the current standard of care for these patients.
